Memorial Sloan-Kettering Cancer Center And Illumina Launch Comprehensive Circulating Tumor DNA Program

NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Memorial Sloan Kettering Cancer Center (MSK) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration to conduct research studies that are critical to understanding the biology of circulating tumor DNA (ctDNA). The studies aim to inform the development of new strategies to diagnose and monitor cancer and to help establish ctDNA as an important marker in the study and eventual treatment of cancer.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC